Norethindrone Acetate/Ethinyl Estradiol has 58 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 22 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Dasabuvir, Ombitasvir, Ombitasvir/Paritaprevir/Ritonavir. Patients taking Norethindrone Acetate/Ethinyl Estradiol should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 58
- Contraindicated
- 5
- Major
- 22
- Moderate
- 29
Contraindicated (5)
- Norethindrone Acetate/Ethinyl Estradiol + Dasabuvir— Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation Co-administration of norethindrone acetate and eth…
- Norethindrone Acetate/Ethinyl Estradiol + Ombitasvir— Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation Co-administration of norethindrone acetate and eth…
- Norethindrone Acetate/Ethinyl Estradiol + Ombitasvir/Paritaprevir/Ritonavir— Coadministration is contraindicated due to potential for ALT elevations and risk of liver enzyme elevation.
- Norethindrone Acetate/Ethinyl Estradiol + Paritaprevir— Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation Co-administration of norethindrone acetate and eth…
- Norethindrone Acetate/Ethinyl Estradiol + Ritonavir— Concomitant Use with HCV Combination Therapy - Liver Enzyme Elevation Co-administration of norethindrone acetate and eth…
Major (22)
- Norethindrone Acetate/Ethinyl Estradiol + Amprenavir— (Fos)amprenavir/ritonavir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive …
- Norethindrone Acetate/Ethinyl Estradiol + Barbiturates— May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.
- Norethindrone Acetate/Ethinyl Estradiol + Boceprevir— Boceprevir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effectiveness.
- Norethindrone Acetate/Ethinyl Estradiol + Bosentan— May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.
- Norethindrone Acetate/Ethinyl Estradiol + Carbamazepine— Carbamazepine increases metabolism of ethinyl estradiol and/or norethindrone, potentially reducing contraceptive effecti…
- Norethindrone Acetate/Ethinyl Estradiol + Darunavir— Darunavir/ritonavir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effect…
- Norethindrone Acetate/Ethinyl Estradiol + Felbamate— May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.
- Norethindrone Acetate/Ethinyl Estradiol + Glecaprevir And Pibrentasvir— Coadministration is not recommended due to potential for ALT elevations.
- Norethindrone Acetate/Ethinyl Estradiol + Griseofulvin— May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.
- Norethindrone Acetate/Ethinyl Estradiol + Lamotrigine— Hormonal products significantly decrease plasma concentration of lamotrigine, likely reducing seizure control; dosage ad…
- Norethindrone Acetate/Ethinyl Estradiol + Lopinavir— Lopinavir/ritonavir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effect…
- Norethindrone Acetate/Ethinyl Estradiol + Nelfinavir— Nelfinavir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effectiveness.
- Norethindrone Acetate/Ethinyl Estradiol + Nevirapine— Nevirapine decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effectiveness.
- Norethindrone Acetate/Ethinyl Estradiol + Oxcarbazepine— May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.
- Norethindrone Acetate/Ethinyl Estradiol + Phenobarbital— Phenobarbital increases metabolism of ethinyl estradiol and/or norethindrone, potentially reducing contraceptive effecti…
- Norethindrone Acetate/Ethinyl Estradiol + Phenytoin— Phenytoin increases metabolism of ethinyl estradiol and/or norethindrone, potentially reducing contraceptive effectivene…
- Norethindrone Acetate/Ethinyl Estradiol + Rifampin— Rifampin increases metabolism of norethindrone and ethinyl estradiol, reducing contraceptive effectiveness and increasin…
- Norethindrone Acetate/Ethinyl Estradiol + St. John'S Wort— St. John's Wort may induce hepatic enzymes and p-glycoprotein transporter, reducing contraceptive effectiveness and incr…
- Norethindrone Acetate/Ethinyl Estradiol + Telaprevir— Telaprevir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effectiveness.
- Norethindrone Acetate/Ethinyl Estradiol + Tipranavir— Tipranavir/ritonavir decreases plasma concentrations of estrogen and progestin, potentially reducing contraceptive effec…
- Norethindrone Acetate/Ethinyl Estradiol + Topiramate— May decrease contraceptive effectiveness and increase breakthrough bleeding through CYP3A4 induction.
- Norethindrone Acetate/Ethinyl Estradiol + Troglitazone— Troglitazone reduces plasma concentrations of norethindrone and ethinyl estradiol by approximately 30%, potentially redu…
Moderate (29)
- Norethindrone Acetate/Ethinyl Estradiol + Acetaminophen— May increase plasma ethinyl estradiol concentration, possibly by inhibition of conjugation.
- Norethindrone Acetate/Ethinyl Estradiol + Ampicillin— Pregnancy while taking combined oral contraceptives has been reported with ampicillin, though clinical studies have not …
- Norethindrone Acetate/Ethinyl Estradiol + Aprepitant— May decrease plasma concentrations of COCs and diminish contraceptive effectiveness or increase breakthrough bleeding.
- Norethindrone Acetate/Ethinyl Estradiol + Ascorbic Acid— May increase plasma ethinyl estradiol concentration, possibly by inhibition of conjugation.
- Norethindrone Acetate/Ethinyl Estradiol + Atazanavir— Atazanavir/ritonavir increases plasma concentrations of estrogen and progestin.
- Norethindrone Acetate/Ethinyl Estradiol + Atorvastatin— Coadministration increases AUC of norethindrone by approximately 30% and ethinyl estradiol by approximately 20%.
- Norethindrone Acetate/Ethinyl Estradiol + Clarithromycin— CYP3A4 inhibitor may increase plasma concentration of estrogen or progestin and may result in adverse reactions.
- Norethindrone Acetate/Ethinyl Estradiol + Clofibrate— Oral contraceptives may induce conjugation of clofibric acid, increasing its clearance and decreasing plasma concentrati…
- Norethindrone Acetate/Ethinyl Estradiol + Cyclosporine— Oral contraceptives may inhibit metabolism of cyclosporine, increasing its plasma concentrations.
- Norethindrone Acetate/Ethinyl Estradiol + Erythromycin— CYP3A4 inhibitor may increase plasma concentration of estrogen or progestin and may result in adverse reactions.
- Norethindrone Acetate/Ethinyl Estradiol + Etravirine— Etravirine increases plasma concentrations of estrogen and progestin.
- Norethindrone Acetate/Ethinyl Estradiol + Fluconazole— May increase plasma hormone concentrations.
- Norethindrone Acetate/Ethinyl Estradiol + Grapefruit Juice— CYP3A4 inhibitor may increase plasma concentration of estrogen or progestin and may result in adverse reactions.
- Norethindrone Acetate/Ethinyl Estradiol + Indinavir— Indinavir increases plasma concentrations of estrogen and progestin.
- Norethindrone Acetate/Ethinyl Estradiol + Itraconazole— CYP3A4 inhibitor may increase plasma concentration of estrogen or progestin and may result in adverse reactions.
- Norethindrone Acetate/Ethinyl Estradiol + Ketoconazole— CYP3A4 inhibitor may increase plasma concentration of estrogen or progestin and may result in adverse reactions.
- Norethindrone Acetate/Ethinyl Estradiol + Morphine— Oral contraceptives may induce conjugation of morphine, increasing its clearance and decreasing plasma concentrations.
- Norethindrone Acetate/Ethinyl Estradiol + Phenylbutazone— Reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding have been suggested.
- Norethindrone Acetate/Ethinyl Estradiol + Prednisolone— Oral contraceptives may inhibit metabolism of prednisolone, increasing its plasma concentrations.
- Norethindrone Acetate/Ethinyl Estradiol + Rifabutin— May decrease plasma concentrations of COCs and diminish contraceptive effectiveness or increase breakthrough bleeding.
- Norethindrone Acetate/Ethinyl Estradiol + Rosuvastatin— Increases AUC values for ethinyl estradiol by approximately 20 to 25%.
- Norethindrone Acetate/Ethinyl Estradiol + Rufinamide— May decrease plasma concentrations of COCs and diminish contraceptive effectiveness or increase breakthrough bleeding.
- Norethindrone Acetate/Ethinyl Estradiol + Salicylic Acid— Oral contraceptives may induce conjugation of salicylic acid, increasing its clearance and decreasing plasma concentrati…
- Norethindrone Acetate/Ethinyl Estradiol + Temazepam— Oral contraceptives may induce conjugation of temazepam, increasing its clearance and decreasing plasma concentrations.
- Norethindrone Acetate/Ethinyl Estradiol + Tetracycline— Pregnancy while taking combined oral contraceptives has been reported with tetracycline, though clinical studies have no…
- Norethindrone Acetate/Ethinyl Estradiol + Theophylline— Oral contraceptives may inhibit metabolism of theophylline, increasing its plasma concentrations.
- Norethindrone Acetate/Ethinyl Estradiol + Thyroid Hormones— Women on thyroid hormone replacement therapy may need increased doses due to increased serum thyroid-binding globulin wi…
- Norethindrone Acetate/Ethinyl Estradiol + Tizanidine— Ethinyl estradiol may inhibit tizanidine metabolism and increase its plasma concentration.
- Norethindrone Acetate/Ethinyl Estradiol + Voriconazole— Ethinyl estradiol may inhibit voriconazole metabolism and increase its plasma concentration.